Influenza vaccine effectiveness within prospective cohorts of healthcare personnel in Israel and Peru 2016-2019

Vaccine. 2021 Nov 16;39(47):6956-6967. doi: 10.1016/j.vaccine.2021.07.077. Epub 2021 Sep 9.

Abstract

Background: There are limited data on influenza vaccine effectiveness (IVE) in preventing laboratory-confirmed influenza illness among healthcare personnel (HCP).

Methods: HCP with direct patient contact working full-time in hospitals were followed during three influenza seasons in Israel (2016-2017 to 2018-2019) and Peru (2016 to 2018). Trivalent influenza vaccines were available at all sites, except during 2018-2019 when Israel used quadrivalent vaccines; vaccination was documented by electronic medical records, vaccine registries, and/or self-report (for vaccinations outside the hospital). Twice-weekly active surveillance identified acute respiratory symptoms or febrile illness (ARFI); self-collected respiratory specimens were tested by real-time reverse transcription polymerase chain reaction (PCR) assay. IVE was 100 × 1-hazard ratio (adjusted for sex, age, occupation, and hospital).

Results: Among 5,489 HCP who contributed 10,041 person-seasons, influenza vaccination coverage was 47% in Israel and 32% in Peru. Of 3,056 ARFIs in Israel and 3,538 in Peru, A or B influenza virus infections were identified in 205 (7%) in Israel and 87 (2.5%) in Peru. IVE against all viruses across seasons was 1% (95% confidence interval [CI] = -30%, 25%) in Israel and 12% (95% CI = -61%, 52%) in Peru.

Conclusion: Estimates of IVE were null using person-time models during six study seasons in Israel and Peru.

Keywords: Healthcare; Influenza; Vaccine effectiveness.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Delivery of Health Care
  • Humans
  • Influenza Vaccines*
  • Influenza, Human* / epidemiology
  • Influenza, Human* / prevention & control
  • Israel / epidemiology
  • Peru / epidemiology
  • Prospective Studies
  • Seasons
  • Vaccination
  • Vaccine Efficacy

Substances

  • Influenza Vaccines

Grants and funding